Healthcare industry in India is one of the fastest growing one and presents tremendous opportunity for entrepreneurship across the entire spectrum. The industry is projected to grow to $ 280 billion by 2020 from the current level of $ 100 B. That is an outstanding growth opportunity by any measure and therefore entrepreneurs could potentially choose any segment within the industry and there will be a definite need there.
From, chronic disease management to single specialty chains, from tech platform for health services to EMR/EHR start-ups along with a range of innovative medical devices, we are seeing the entire spectrum covered with start-ups.
So, while the opportunity is unprecedented and very large, the challenges in India are formidable.
Any one who thought that creating an "App" will enable them to create a healthcare company has realized how wide off the mark that thinking was.
- Mr. Pradeep K Jaisingh, Founder & Chairman, HealthStart, India
Patient safety has been conceptualized as the avoidance, prevention and amelioration of adverse outcomes or
injuries stemming from structure & processes. Safety issues in medication, infection control surgery & anesthesia,
transfusion, restraints, staffing & competencies, credentialing and privileging , clinical governance, fire and
non-fire safety, medical equipment, emergency management and security, etc. need to be addressed. The IOM
(1999) pointed out the systemic problems such as poor communication, lack of knowledge in using information
technology, failure of all health professionals to work together, etc. in healthcare lead to poor outcomes. The
report suggested ways to reinvent the health system through six aims for care: safety, timeliness, efficiency,
effectiveness, equity and patient-centered. Better documentation, communication and process improvement
would improve the Doctor- Patient relationship.
Accreditation has systematized and brought changes upon healthcare approach in developing a Safety Mindset.
The accreditation process promotes risk management and patient safety by establishing operational systems and
processes designed to minimize likelihood of errors and maximize likelihood of intercepting errors when occur
or before they occur. Reduction in variation in administrative and clinical processes leading to better quality
care and better outcome. Accreditation in itself is not a goal; the goal is to improve the quality of services by
imbedding patient safety processes into healthcare. Best practices, frugal innovations and use of technology can
make healthcare cost-effective.
- Dr K K Kalra, Chief Executive Officer | NABH National Accreditation Board for Hospitals & ealthcare Providers Quality Council of India, New Delhi, India
Kidney disease is the laggard entrant into the Non communicable disease epidemic unfolding in India. Chronic kidney disease in its advanced stage has complex treatment options: Kidney Transplantation or Dialysis. Since the former is dependent on availability of human organs for which considerable shortage exists, Hemodialysis is the dominant modality offered. Hemodialysis is technology intensive, dependent on skilled labour and expensive therapy. Globally, in developed and emerging economies,
it is either fully funded or partially funded by public financing. In Indian context, there is a huge unmet need with a large gap between growing demand from the steady rise in disease prevalence and meagre service provision: only about 15 % of patients with Kidney disease receive dialysis. Low awareness and acceptance by patients, cost of care, lack of third party payers, limited public provision
and minimal hospital based provision in urban areas only are overbearing challenges in kidney care.
But the escalating demand and changing dynamics of stake holders in health care in India is creating a compulsive need for a paradigm shift in delivery care models. Wider accessibility, rapid scaling up of skilled manpower, cost effective technology, best practices are essential to improve patient safety and outcome. The recent shift of focus in health care policy on this space is bound to accelerate the momentum to find timely and effective solutions for kidney care in India.
- Dr. Suresh Sankar, Chief Medical officer, Davita Renal Care, Chennai, India
Increasingly medical technology is becoming a key enabler of healthcare right from prevention to
treatment. While the rapid advances in technology have enhanced the precision & efficacy of healthcare
interventions, it has also attracted criticism around “over-use” or over dependence on these modern
technological tools, leading to enhancement in healthcare costs. In Indian context, this issue of
affordability gains alarming proportion given over 60% population pays out of pocket. To add to the
problem is the healthcare infrastructure skews resulting in virtual migration of patients from rural and
semi-urban settings to big cities thereby increasing the financial burden further.
With above back-drop in view the talk will attempt to discuss some of the opportunities that lie
underneath these seemingly formidable challenges and how medical technology can be optimally
adopted and utilized to provide solutions for the Indian healthcare sector
- Mr. Ashok K Kakkar, Senior Managing Director, Varian Medical Systems International India Pvt. Ltd., Mumbai
Currently valued at USD 14.7 bn the domestic Pharmaceutical Market is growing at 14%. It is a highly fragmented market with over 3,000 companies (of which 550 are covered by IMS) and over 30,000 brands. Indian companies contribute to ~75% ofthe total market. The market is predominantly branded generics (~ 80%) with an average of 100 plus brands competing for doctor's attention for every commercialized molecule. While patented products account for about 1% of the market, the market has witnessed a number of patent related litigations over the vears.
The prices of pharmaceuticals in India are one ofthe lowest in the world, on account ofsevere competition from local companies by the virtue of strong reverse engineering capabilities. In addition, the operating environment is not fully conducive on account ofthe governmental price controls. dated legislations, unionized trade (about 7,00,000 traditional pharmacies) and ﬁeid force (medical reps).
India has maximum numberof USFDA approved plants outside of US and exports pharmaceutical products to over
200 countries contributing to U5$ 15.5 billion revenues. india has been able to leverage its reverse engineering capabilities to tap the international market, carry out contract manufacturing and contract research. However, we are still on our journey to create a new drug discovery that is fully homegrown!
The reach of pharmaceutical products to the large Indian population is still a concern. Over the years,there
has been little innovation in the delivery of healthcare to the last mile! India needs higher healthcare spends
by Government, enhanced efficiency of delivery networks, better utilization of technology, more Public Private Partnerships, engagement with academia to establish models (eg. Intellectual property, technology transfer processes) and better governmental incentives to enhance sectoral investments to take the Industry to the next level.
- Mr Jawed Zia, Head CPO & Country President, Novartis India
The CMHS seminar held at Wing 11 Faculty Lounge, IIM Ahmedabad on Friday, July 10, 2015 by Dr. Neha Kumar, Assistant Professor, Georgia Institute of Technology (Atlanta, Georgia, United States)
- Kumar, Neha
The CMHS seminar held at Wing 11 Faculty Lounge, IIM Ahmedabad on Thursday, April 16, 2015 by Dr. Taslimarif Saiyad, Director and COO at the Centre for Cellular and Molecular Platforms(C-CAMP), Dept. of Biotechnology, Govt. of India initiative, Bangalore, India
- Saiyad, Taslimarif
The CMHS seminar held at Wing 11 Faculty Lounge, IIM Ahmedabad on Friday, February 13, 2015 by Dr. Sidhartha Satpathy, Professor & Head of Department of Hospital Administration AIIMS, New Delhi
- Satpathy, Sidhartha